NCT04306393View on ClinicalTrials.gov

Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 21, 2020

Primary Completion Date

December 21, 2021

Study Completion Date

June 15, 2022

Conditions
SARS (Severe Acute Respiratory Syndrome)Coronavirus
Interventions
DRUG

Nitric Oxide Gas

"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively."

Trial Locations (5)

18288

Danderyd Sjukhus AB, Danderyd

35294

University of Alabama, Birmingham

71103

Louisiana State University Health Shreveport, Shreveport

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Xijing Hospital

OTHER

collaborator

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER

collaborator

Niguarda Hospital

OTHER

lead

Massachusetts General Hospital

OTHER

NCT04306393 - Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | Biotech Hunter | Biotech Hunter